Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...
To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10373/251904_9ea3c480f4166aa2_001full.jpg "My family has a history of ...
Hosted on MSN
Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module
Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
Comparison of quantitative functional RAD51 foci and genomic alterations in predicting PARPi response in mCRPC: A multicenter real-world study.
Men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle, despite no reduction in prostate cancer-specific mortality, according to a large observational study. A ...
The MarketWatch News Department was not involved in the creation of this content. Louisville, Kentucky--(Newsfile Corp. - May 19, 2025) - Aura Wellness today announced groundbreaking research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results